Eric W-F Lam

List of Publications by Year in Descending Order

264 papers	18,400 citations	74 h-index	126 g-index
281 ext. papers	20,660 ext. citations	8.4 avg, IF	6.72 L-index

#	Paper	IF	Citations
264	Smad3 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast Transition (Adv. Sci. 1/2022). *Advanced Science*, **2022**, 9, 2270005	13.6	
263	Smad3 Promotes Cancer-Associated Fibroblasts Generation via Macrophage-Myofibroblast Transition. *Advanced Science*, **2021**, e2101235	13.6	8
262	KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype. *Nature Aging*, **2021**, 1, 454-472		4
261	Cancer and stress: NextGen strategies. *Brain, Behavior, and Immunity*, **2021**, 93, 368-383	16.6	7
260	Therapeutic strategies targeting FOXO transcription factors. *Nature Reviews Drug Discovery*, **2021**, 20, 21-38	64.1	48
259	Oncogenic AURKA-enhanced N-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. *Cell Research*, **2021**, 31, 345-361	24.7	26
258	CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer. *Cancer Communications*, **2021**, 41, 121-139	9.4	8
257	Altered Serum Metabolic Profile Assessed by Advanced 1H-NMR in Breast Cancer Patients. *Cancers*, **2021**, 13,	6.6	2
256	Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma. *Signal Transduction and Targeted Therapy*, **2021**, 6, 333	21	2
255	Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition. *Cell Death and Disease*, **2021**, 12, 893	9.8	1
254	Cancer cell immune mimicry delineates onco-immunologic modulation. *IScience*, **2021**, 24, 103133	6.1	0
253	USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages. *Molecular Therapy - Oncolytics*, **2021**, 23, 26-37	6.4	3
252	ADO/hypotaurine: a novel metabolic pathway contributing to glioblastoma development. *Cell Death Discovery*, **2021**, 7, 21	6.9	4
251	Liposomal Thiostrepton Formulation and Its Effect on Breast Cancer Growth Inhibition. *Journal of Pharmaceutical Sciences*, **2021**, 110, 2508-2516	3.9	3
250	Senescent Stromal Cells Promote Cancer Resistance through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles. *Cancer Research*, **2020**, 80, 3383-3398	10.1	24
249	FOXO transcription factor family in cancer and metastasis. *Cancer and Metastasis Reviews*, **2020**, 39, 681-709	9.6	45
248	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. *Cancers*, **2020**, 12,	6.6	4

247	Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival. *Molecular and Cellular Endocrinology*, **2020**, 515, 110932	4.4	2
246	Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer. *Oncogene*, **2020**, 39, 3206-3217	9.2	4
245	ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. *Nucleic Acids Research*, **2020**, 48, 2676-2693	20.1	13
244	Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases. *Trends in Biochemical Sciences*, **2020**, 45, 578-592	10.3	55
243	Multifaceted Oncogenic Role of Adipocytes in the Tumour Microenvironment. *Advances in Experimental Medicine and Biology*, **2020**, 1219, 125-142	3.6	3
242	Transforming Growth Factor-□A Multifunctional Regulator of Cancer Immunity. *Cancers*, **2020**, 12,	6.6	20
241	NEDDylation negatively regulates ERR□expression to promote breast cancer tumorigenesis and progression. *Cell Death and Disease*, **2020**, 11, 703	9.8	4
240	Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis. *Molecular Cancer*, **2020**, 19, 138	42.1	46
239	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. *Oncogene*, **2019**, 38, 3216-3231	9.2	23
238	Activation of Aurora A kinase increases YAP stability via blockage of autophagy. *Cell Death and Disease*, **2019**, 10, 432	9.8	17
237	Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells. *Journal of Clinical Investigation*, **2019**, 129, 1030-1046	15.9	68
236	FOXK2 Transcription Factor and Its Emerging Roles in Cancer. *Cancers*, **2019**, 11,	6.6	25
235	Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. *Biochemical Pharmacology*, **2019**, 163, 391-403	6	2
234	Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors. *Molecular Oncology*, **2019**, 13, 1369-1387	7.9	5
233	Extracellular vesicles in the tumor microenvironment: old stories, but new tales. *Molecular Cancer*, **2019**, 18, 59	42.1	131
232	The prognostic landscape of interactive biological processes presents treatment responses in cancer. *EBioMedicine*, **2019**, 41, 120-133	8.8	4
231	FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. *Scientific Reports*, **2019**, 9, 1505	4.9	49
230	Reduced FOXM1 Expression Limits Trophoblast Migration and Angiogenesis and Is Associated With Preeclampsia. *Reproductive Sciences*, **2019**, 26, 580-590	3	8

229	Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. *Oncogene*, **2019**, 38, 6382-6398	9.2	19
228	Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells. *Oncology Reports*, **2019**, 42, 953-962	3.5	15
227	The Critical Role of Dysregulated RhoB Signaling Pathway in Radioresistance of Colorectal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 1153-1164	4	7
226	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. *Cancers*, **2019**, 11,	6.6	19
225	Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression. *Aging Cell*, **2019**, 18, e13027	9.9	38
224	Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation. *BMC Cancer*, **2019**, 19, 1106	4.8	10
223	Characterization of FOXO Acetylation. *Methods in Molecular Biology*, **2019**, 1890, 77-90	1.4	1
222	Senescent cells: A new Achilles heel to exploit for cancer medicine?. *Aging Cell*, **2019**, 18, e12875	9.9	12
221	BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 3681-3691	12.9	12
220	The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1. *Nature Communications*, **2018**, 9, 1723	17.4	58
219	SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells. *Oncogenesis*, **2018**, 7, 29	6.6	15
218	Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. *Molecular and Cellular Endocrinology*, **2018**, 462, 82-92	4.4	16
217	ER stress and cancer: The FOXO forkhead transcription factor link. *Molecular and Cellular Endocrinology*, **2018**, 462, 67-81	4.4	27
216	Cellular Senescence: The Sought or the Unwanted?. *Trends in Molecular Medicine*, **2018**, 24, 871-885	11.5	84
215	Cyclin D1 depletion interferes with oxidative balance and promotes cancer cell senescence. *Journal of Cell Science*, **2018**, 131,	5.3	16
214	O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1. *Oncogene*, **2018**, 37, 5648-5665	9.2	17
213	Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. *ELife*, **2018**, 7,	8.9	24
212	The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. *Seminars in Cancer Biology*, **2018**, 50, 77-89	12.7	79

211	Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. *Oncogene*, **2018**, 37, 1062-1074	9.2	107
210	Estrogen receptor upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. *Cell Death and Disease*, **2018**, 9, 1120	9.8	38
209	FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. *Cell Death and Disease*, **2018**, 9, 1185	9.8	21
208	Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. *Nature Communications*, **2018**, 9, 4315	17.4	45
207	Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1753-1765	7.4	15
206	p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. *Oncogene*, **2017**, 36, 304-317	9.2	52
205	Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins. *Molecular Carcinogenesis*, **2017**, 56, 208-217	5	68
204	FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. *Oncogene*, **2017**, 36, 3428-3440	9.2	56
203	Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket. *Journal of Medicinal Chemistry*, **2017**, 60, 1928-1945	8.3	39
202	Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. *Oncogenesis*, **2017**, 6, e298	6.6	51
201	Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line. *Scientific Reports*, **2017**, 7, 46079	4.9	14
200	Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. *Leukemia*, **2017**, 31, 2543-2551	10.7	68
199	Dataset of the human homologues and orthologues of lipid-metabolic genes identified as DAF-16 targets their roles in lipid and energy metabolism. *Data in Brief*, **2017**, 11, 606-610	1.2	1
198	Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. *Breast Cancer Research and Treatment*, **2017**, 163, 461-474	4.4	42
197	p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis. *Carcinogenesis*, **2017**, 38, 1092-1103	4.6	30
196	H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. *Cell Death and Disease*, **2017**, 8, e2569	9.8	140
195	Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. *Scientific Reports*, **2017**, 7, 17831	4.9	24
194	OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. *Oncogene*, **2016**, 35, 1433-44	9.2	82

193	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. *Oncogene*, **2016**, 35, 990-1002	9.2	131
192	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment. *Oncogenesis*, **2016**, 5, e252	6.6	22
191	11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 2119-30	4.9	3
190	Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy. *Medicinal Research Reviews*, **2016**, 36, 1036-1079	14.4	117
189	Sirtuin1 (SIRT1) in the Acetylation of Downstream Target Proteins. *Methods in Molecular Biology*, **2016**, 1436, 169-88	1.4	20
188	Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. *Nature Communications*, **2016**, 7, 10180	17.4	96
187	In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs. *Methods in Molecular Biology*, **2016**, 1395, 39-53	1.4	3
186	STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. *Tumor Biology*, **2016**, 37, 5385-95	2.9	15
185	RNA interference as a gene silencing tool to control in tomato (Solanum lycopersicum). *PeerJ*, **2016**, 4, e2673	3.1	36
184	FOXD3 controls pluripotency through modulating enhancer activity. *Stem Cell Investigation*, **2016**, 3, 17	5.1	4
183	Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance. *Current Drug Targets*, **2016**, 17, 164-77	3	43
182	BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. *Oncogenesis*, **2016**, 5, e214	6.6	18
181	Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity. *Journal of Virology*, **2016**, 90, 5915-27	6.6	38
180	FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. *British Journal of Cancer*, **2016**, 115, 1223-1233	8.7	35
179	Loss of Endometrial Plasticity in Recurrent Pregnancy Loss. *Stem Cells*, **2016**, 34, 346-56	5.8	106
178	FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. *Cellular Signalling*, **2015**, 27, 2496-505	4.9	76
177	FOXO3a and Posttranslational Modifications Mediate Glucocorticoid Sensitivity in B-ALL. *Molecular Cancer Research*, **2015**, 13, 1578-90	6.6	21
176	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. *Oncogenesis*, **2015**, 4, e167	6.6	19

175	Automated multiwell fluorescence lifetime imaging for Förster resonance energy transfer assays and high content analysis. *Analytical Methods*, **2015**, 7, 4071-4089	3.2	8
174	FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. *Oncogene*, **2015**, 34, 5012-24	9.2	30
173	The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. *ChemMedChem*, **2015**, 10, 69-82	3.7	53
172	FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs. *International Journal of Oncology*, **2015**, 47, 1230-40	4.4	15
171	The clock protein period 2 synchronizes mitotic expansion and decidual transformation of human endometrial stromal cells. *FASEB Journal*, **2015**, 29, 1603-14	0.9	30
170	The pioneer factor PBX1 is a novel driver of metastatic progression in ER-positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
169	Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. *Cytokine*, **2014**, 68, 94-100	4	37
168	Adenovirus detection by the cGAS/STING/TBK1 DNA sensing cascade. *Journal of Virology*, **2014**, 88, 974-81	6.6	146
167	Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells. *Journal of Virology*, **2014**, 88, 14426-39	6.6	24
166	A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. *Molecular Cancer Therapeutics*, **2014**, 13, 1991-2003	6.1	40
165	FOXM1: A key oncofoetal transcription factor in health and disease. *Seminars in Cancer Biology*, **2014**, 29, 32-9	12.7	95
164	FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2014**, 1839, 1316-22	6	119
163	IKK-restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. *Nature Communications*, **2014**, 5, 3661	17.4	57
162	The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors. *International Journal of Oncology*, **2014**, 45, 1949-58	4.4	10
161	Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. *PLoS ONE*, **2014**, 9, e113478	3.7	57
160	An automated multiwell plate reading flim microscope for live cell autofluorescence lifetime assays. *Journal of Innovative Optical Health Sciences*, **2014**, 07, 1450025	1.2	3
159	SUMOylation inhibits FOXM1 activity and delays mitotic transition. *Oncogene*, **2014**, 33, 4316-29	9.2	66
158	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. *Oncogene*, **2014**, 33, 4144-55	9.2	88

157	Cellular senescence and aging: the role of B-MYB. *Aging Cell*, **2014**, 13, 773-9	9.9	49
156	Forkhead box transcription factors in cancer initiation, progression and chemotherapeutic drug response. *Frontiers in Oncology*, **2014**, 4, 305	5.3	10
155	The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress. *Oncogene*, **2014**, 33, 3183-94	9.2	57
154	FOXM1 Is Overexpressed in B-Acute Lymphoblastic Leukemia (B-All) and Its Inhibition Sensitizes B-All Cells to Chemotherapeutic Drugs. *Blood*, **2014**, 124, 2245-2245	2.2	1
153	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. *Carcinogenesis*, **2013**, 34, 1476-86	4.6	120
152	Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. *Oncogene*, **2013**, 32, 3500-9	9.2	117
151	The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. *Oncogene*, **2013**, 32, 4634-45	9.2	69
150	Forkhead box proteins: tuning forks for transcriptional harmony. *Nature Reviews Cancer*, **2013**, 13, 482-95	31.3	417
149	Progesterone and FOXO1 signaling: harnessing cellular senescence for the treatment of ovarian cancer. *Cell Cycle*, **2013**, 12, 1660-1	4.7	4
148	An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). *Annals of Oncology*, **2013**, 24, 924-30	10.3	11
147	Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. *Chinese Journal of Cancer*, **2013**, 32, 365-70		48
146	Mechanisms of endometrial progesterone resistance. *Molecular and Cellular Endocrinology*, **2012**, 358, 208-15	4.4	115
145	The transcription factor encyclopedia. *Genome Biology*, **2012**, 13, R24	18.3	86
144	FOXM1: From cancer initiation to progression and treatment. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2012**, 1819, 28-37	6	276
143	Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2012**, 1819, 855-62	6	64
142	The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma. *Cytokine*, **2012**, 59, 417-22	4	19
141	Cell-specific regulation of nucleic acid sensor cascades: a controlling interest in the antiviral response. *Journal of Virology*, **2012**, 86, 13303-12	6.6	16
140	Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. *Frontiers of Medicine*, **2012**, 6, 376-80	12	54

139	The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors. *MedChemComm*, **2012**,	5	19
138	A specific role for phosphoinositide 3-kinase and AKT in osteoblasts?. *Frontiers in Endocrinology*, **2012**, 3, 88	5.7	53
137	The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment. *Molecular Cancer Research*, **2012**, 10, 1189-202	6.6	40
136	A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival. *Journal of Immunology*, **2012**, 188, 3920-7	5.3	15
135	The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. *Cancer Discovery*, **2012**, 2, 156-71	24.4	39
134	FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. *Oncogene*, **2012**, 31, 1845-58	9.2	113
133	The diversity of sex steroid action: the role of micro-RNAs and FOXO transcription factors in cycling endometrium and cancer. *Journal of Endocrinology*, **2012**, 212, 13-25	4.7	48
132	Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. *Journal of Biological Chemistry*, **2012**, 287, 1545-55	5.4	97
131	Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters. *Nucleic Acids Research*, **2012**, 40, 7776-87	20.1	10
130	Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis. *Blood*, **2012**, 120, 1215-1215	2.2	
129	Sense and sensitivity: FOXO and ROS in cancer development and treatment. *Antioxidants and Redox Signaling*, **2011**, 14, 675-87	8.4	57
128	NADPH oxidase-derived reactive oxygen species mediate decidualization of human endometrial stromal cells in response to cyclic AMP signaling. *Endocrinology*, **2011**, 152, 730-40	4.8	41
127	ER□ represses FOXM1 expression through targeting ER□ to control cell proliferation in breast cancer. *American Journal of Pathology*, **2011**, 179, 1148-56	5.8	27
126	Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. *Drug Resistance Updates*, **2011**, 14, 35-44	23.2	73
125	FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. *Current Drug Targets*, **2011**, 12, 1256-66	3	62
124	FLIM FRET technology for drug discovery: automated multiwell-plate high-content analysis, multiplexed readouts and application in situ. *ChemPhysChem*, **2011**, 12, 609-26	3.2	49
123	iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. *Clinical Cancer Research*, **2011**, 17, 6924-33	12.9	53
122	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. *Molecular Cancer Therapeutics*, **2011**, 10, 1046-58	6.1	115

121	Rapid temporal control of Foxp3 protein degradation by sirtuin-1. *PLoS ONE*, **2011**, 6, e19047	3.7	94
120	FOXO transcription factors and their role in disorders of the female reproductive tract. *Current Drug Targets*, **2011**, 12, 1291-302	3	16
119	Review: lapatinib in metastatic colorectal cancer-another strategy for disease control?. *Clinical Advances in Hematology and Oncology*, **2011**, 9, 500-1	0.6	2
118	Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. *PLoS ONE*, **2010**, 5, e12293	3.7	84
117	FOXM1 confers acquired cisplatin resistance in breast cancer cells. *Molecular Cancer Research*, **2010** , 8, 24-34	6.6	157
116	Butyrate-rich colonic microenvironment is a relevant selection factor for metabolically adapted tumor cells. *Journal of Biological Chemistry*, **2010**, 285, 39211-23	5.4	48
115	Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. *Cancer Research*, **2010**, 70, 367-77	10.1	272
114	Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. *Haematologica*, **2010**, 95, 1081-9	6.6	119
113	The biological effects of C/EBPalpha in K562 cells depend on the potency of the N-terminal regulatory region, not on specificity of the DNA binding domain. *Journal of Biological Chemistry*, **2010**, 285, 30837-50	5.4	10
112	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2670-3	5.9	9
111	Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. *Molecular Cancer*, **2010**, 9, 318	42.1	35
110	SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. *Molecular Cancer Therapeutics*, **2010**, 9, 844-55	6.1	331
109	The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. *Cytokine*, **2010**, 49, 134-40	4	31
108	Silencing of the JNK pathway maintains progesterone receptor activity in decidualizing human endometrial stromal cells exposed to oxidative stress signals. *FASEB Journal*, **2010**, 24, 1541-51	0.9	70
107	The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). *Virology*, **2010**, 400, 44-52	3.6	32
106	Sustained spindle-assembly checkpoint response requires de novo transcription and translation of cyclin B1. *PLoS ONE*, **2010**, 5, e13037	3.7	26
105	Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. *Oncogene*, **2009**, 28, 721-33	9.2	46
104	The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells. *FEBS Journal*, **2009**, 276, 4037-50	5.7	6

103	CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. *Molecular Immunology*, **2009**, 46, 1727-35	4.3	14
102	Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation. *Breast Cancer Research*, **2009**, 11, R79	8.3	25
101	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 582-91	6.1	110
100	FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. *International Journal of Oncology*, **2009**, 35, 57-68	1	70
99	BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. *Blood*, **2009**, 113, 2302-11	2.2	29
98	Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. *Methods in Molecular Biology*, **2009**, 462, 201-11	1.4	14
97	FOXO transcription factors: from cell fate decisions to regulation of human female reproduction. *Advances in Experimental Medicine and Biology*, **2009**, 665, 227-41	3.6	34
96	Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. *Oncogene*, **2008**, 27, 9-19	9.2	108
95	Many forks in the path: cycling with FoxO. *Oncogene*, **2008**, 27, 2300-11	9.2	142
94	Targeting FOXM1. *Nature Reviews Cancer*, **2008**, 8, 242	31.3	44
93	The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. *Endocrinology*, **2008**, 149, 4462-74	4.8	122
92	Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. *Molecular Cancer Therapeutics*, **2008**, 7, 2022-32	6.1	177
91	FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells. *Molecular Cancer Therapeutics*, **2008**, 7, 3237-46	6.1	103
90	Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. *Molecular Cancer Therapeutics*, **2008**, 7, 670-8	6.1	148
89	Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. *Cell Cycle*, **2008**, 7, 3133-6	4.7	70
88	Identification of cyclin A2 as the downstream effector of the nuclear phosphatidylinositol 4,5-bisphosphate signaling network. *Journal of Biological Chemistry*, **2008**, 283, 5477-85	5.4	7
87	FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. *Journal of Biological Chemistry*, **2008**, 283, 16545-53	5.4	80
86	The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. *Molecular and Cellular Biology*, **2008**, 28, 5886-98	4.8	124

85	Promiscuous and lineage-specific roles of cell cycle regulators in haematopoiesis. *Cell Division*, **2007**, 2, 6	2.8	8
84	The emerging roles of forkhead box (Fox) proteins in cancer. *Nature Reviews Cancer*, **2007**, 7, 847-59	31.3	809
83	Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. *Leukemia*, **2007**, 21, 304-10	10.7	317
82	Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. *British Journal of Haematology*, **2007**, 139, 243-54	4.5	15
81	Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. *Cancer Research*, **2007**, 67, 3955-62	10.1	123
80	FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. *Journal of Biological Chemistry*, **2007**, 282, 2211-20	5.4	68
79	Role and regulation of the serum- and glucocorticoid-regulated kinase 1 in fertile and infertile human endometrium. *Endocrinology*, **2007**, 148, 5020-9	4.8	58
78	Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. *Molecular and Cellular Biology*, **2007**, 27, 4917-30	4.8	143
77	The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. *Molecular Cancer Therapeutics*, **2007**, 6, 3169-79	6.1	71
76	Latent protein LANA2 from Kaposi sarcoma-associated herpesvirus interacts with 14-3-3 proteins and inhibits FOXO3a transcription factor. *Journal of Virology*, **2007**, 81, 1511-6	6.6	39
75	Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. *Transplantation*, **2007**, 83, 71-6	1.8	337
74	Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. *Molecular Endocrinology*, **2007**, 21, 2334-49		155
73	Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. *Molecular Endocrinology*, **2006**, 20, 35-44		113
72	Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. *Molecular Endocrinology*, **2006**, 20, 2444-55		143
71	Heparin prevents programmed cell death in human trophoblast. *Molecular Human Reproduction*, **2006**, 12, 237-43	4.4	94
70	In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3deoxy-3[18F]fluorothymidine positron emission tomography. *Cancer Research*, **2006**, 66, 7621-9	10.1	64
69	Chronic protein kinase B (PKB/c-akt) activation leads to apoptosis induced by oxidative stress-mediated Foxo3a transcriptional up-regulation. *Cancer Research*, **2006**, 66, 10760-9	10.1	54
68	Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A. *Journal of Virology*, **2006**, 80, 11191-9	6.6	22

67	Human homologs of the putative G protein-coupled membrane progestin receptors (mPRalpha, beta, and gamma) localize to the endoplasmic reticulum and are not activated by progesterone. *Molecular Endocrinology*, **2006**, 20, 3146-64		94
66	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. *Cancer Research*, **2006**, 66, 212-20	10.1	202
65	Regulation of the SUMO pathway sensitizes differentiating human endometrial stromal cells to progesterone. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 16272-7	11.5	89
64	p27Kip1 and p130 cooperate to regulate hematopoietic cell proliferation in vivo. *Molecular and Cellular Biology*, **2006**, 26, 6170-84	4.8	15
63	The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. *Journal of Biological Chemistry*, **2006**, 281, 25167-76	5.4	131
62	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. *Molecular Cancer*, **2006**, 5, 40	42.1	38
61	The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. *Molecular Cancer*, **2006**, 5, 7	42.1	52
60	Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. *Molecular Cancer*, **2006**, 5, 8	42.1	66
59	A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). *ACS Chemical Biology*, **2006**, 1, 780-90	4.9	113
58	Inflammation and sex steroid receptors: a motif for change. *Cell*, **2006**, 124, 466-8	56.2	3
57	FOXO transcription factors: key regulators of cell fate. *Biochemical Society Transactions*, **2006**, 34, 722-6	5.1	181
56	Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. *Oncogene*, **2006**, 25, 2170-80	9.2	43
55	FOXO transcription factors **2006**, 207-236		
54	Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. *Blood*, **2005**, 105, 2821-7	2.2	901
53	Regulated expression of putative membrane progestin receptor homologues in human endometrium and gestational tissues. *Journal of Endocrinology*, **2005**, 187, 89-101	4.7	106
52	Quiescence and functional reprogramming of Epstein-Barr virus (EBV)-specific CD8+ T cells during persistent infection. *Blood*, **2005**, 106, 558-65	2.2	41
51	Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. *Oncogene*, **2005**, 24, 2317-29	9.2	245
50	Phosphatidylinositol 3-kinase is required for the transcriptional activation of cyclin D2 in BCR activated primary mouse B lymphocytes. *European Journal of Immunology*, **2005**, 35, 2748-61	6.1	13

49	ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. *Journal of Biological Chemistry*, **2005**, 280, 3185-96	5.4	54
48	Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells. *Journal of Biological Chemistry*, **2005**, 280, 37310-8	5.4	22
47	Convergence of interferon-gamma and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription-y). *Molecular Endocrinology*, **2004**, 18, 1988-99		24
46	Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance. *Journal of Biological Chemistry*, **2004**, 279, 7636-42	5.4	36
45	FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. *Molecular and Cellular Biology*, **2004**, 24, 10058-71	4.8	145
44	The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. *Clinical Cancer Research*, **2004**, 10, 2421-8	12.9	57
43	The expression of oestrogen receptor (ER)-beta and its variants, but not ERalpha, in adult human mammary fibroblasts. *Journal of Molecular Endocrinology*, **2004**, 33, 35-50	4.5	43
42	Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. *Clinical Cancer Research*, **2004**, 10, 8094-104	12.9	95
41	Vav-dependent and vav-independent phosphatidylinositol 3-kinase activation in murine B cells determined by the nature of the stimulus. *Journal of Immunology*, **2004**, 173, 3209-14	5.3	42
40	Androgens target prohibitin to regulate proliferation of prostate cancer cells. *Oncogene*, **2004**, 23, 2996-3004	7.2	87
39	Steroid receptor action. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2004**, 18, 265-82	4.6	47
38	Value of SERMs in postmenopausal women. *Lancet, The*, **2004**, 363, 1477-8	40	3
37	Cyclin D2 controls B cell progenitor numbers. *Journal of Leukocyte Biology*, **2003**, 74, 1139-43	6.5	22
36	Commitment point during G0-->G1 that controls entry into the cell cycle. *Molecular and Cellular Biology*, **2003**, 23, 2351-61	4.8	84
35	BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. *Oncogene*, **2003**, 22, 2248-59	9.2	55
34	Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. *Oncogene*, **2003**, 22, 7600-6	9.2	138
33	FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. *Journal of Biological Chemistry*, **2003**, 278, 49795-805	5.4	396
32	FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. *Journal of Cell Biology*, **2002**, 156, 531-42	7.3	307

31	H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. *Journal of Biological Chemistry*, **2002**, 277, 13761-70	5.4	131
30	Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1. *Journal of Biological Chemistry*, **2002**, 277, 32413-6	5.4	20
29	Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. *Molecular and Cellular Biology*, **2002**, 22, 7842-52	4.8	455
28	Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. *Molecular and Cellular Biology*, **2002**, 22, 2025-36	4.8	371
27	An E2F-binding site mediates the activation of the proliferative isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by phosphatidylinositol 3-kinase. *Biochemical Journal*, **2002**, 368, 283-91	3.8	8
26	The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. *Blood*, **2001**, 97, 2604-10	2.2	42
25	BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells. *Oncogene*, **2001**, 20, 7352-67	9.2	57
24	Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen Receptor. *Journal of Biological Chemistry*, **2001**, 276, 41040-8	5.4	30
23	BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. *Journal of Biological Chemistry*, **2001**, 276, 23572-80	5.4	88
22	BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir. *Molecular Therapy*, **2001**, 3, 642-52	11.7	6
21	Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. *Cancer Research*, **2001**, 61, 8005-13	10.1	31
20	Ligation of the WC1 receptor induces gamma delta T cell growth arrest through fumonisin B1-sensitive increases in cellular ceramide. *Journal of Immunology*, **2000**, 165, 3564-70	5.3	10
19	Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. *Journal of Biological Chemistry*, **2000**, 275, 21960-8	5.4	203
18	Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. *International Immunology*, **2000**, 12, 631-8	4.9	113
17	Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). *Molecular and Cellular Biology*, **2000**, 20, 9138-48	4.8	547
16	Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. *Journal of Biological Chemistry*, **2000**, 275, 3479-84	5.4	96
15	Modulation of E2F complexes during G0 to S phase transition in human primary B-lymphocytes. *Journal of Biological Chemistry*, **1999**, 274, 12009-16	5.4	21
14	Rapid dephosphorylation of p107 following UV irradiation. *Oncogene*, **1999**, 18, 679-88	9.2	39

13	Different functions are required for initiation and maintenance of immortalization of rat embryo fibroblasts by SV40 large T antigen. *Oncogene*, **1999**, 18, 7343-50	9.2	21
12	Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. *European Journal of Immunology*, **1999**, 29, 3380-9	6.1	21
11	The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter. *Journal of Biological Chemistry*, **1998**, 273, 10972-8	5.4	25
10	Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells. *Journal of Biological Chemistry*, **1998**, 273, 10051-7	5.4	18
9	Transcription factor E2F controls the reversible gamma delta T cell growth arrest mediated through WC1. *Journal of Immunology*, **1998**, 161, 1630-6	5.3	12
8	CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. *International Reviews of Immunology*, **1997**, 15, 5-31	4.6	28
7	Cell-cycle regulation of human B-myb transcription. *Gene*, **1995**, 160, 277-81	3.8	75
6	DP and E2F proteins: coordinating transcription with cell cycle progression. *Current Opinion in Cell Biology*, **1994**, 6, 859-66	9	177
5	Transcription regulation by murine B-myb is distinct from that by c-myb. *Nucleic Acids Research*, **1993**, 21, 267-72	20.1	71
4	Characterization and cell cycle-regulated expression of mouse B-myb. *Oncogene*, **1992**, 7, 1885-90	9.2	63
3	Forkhead box proteins: the tuning forks in cancer development and treatment328-335		
2	Senescent stromal cells promote cancer resistance through SIRT1 loss-potentiated overproduction of small extracellular vesicles		1
1	KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype		2